Are there active ibogaine clinical trials?

Yes. Multiple Phase 2 trials are underway studying ibogaine for opioid use disorder and treatment-resistant depression. Major institutions including Stanford and Johns Hopkins are involved in research.

Can I enroll in an ibogaine clinical trial?

Clinical trial enrollment depends on the specific study's inclusion criteria, your medical history, and your location. Check ClinicalTrials.gov or use our tracker for current recruiting studies.

Is ibogaine FDA-approved?

No. Ibogaine is not FDA-approved. It is classified as a Schedule I substance in the United States. Clinical trials are the pathway toward potential FDA approval.

🧬 Clinical Trials Database

Explore active and completed ibogaine research studies worldwide

Medically reviewed: March 2026|By: Dr. Lisa Nakamura, PhD, Neuroscience(Neuroscience & Neuroplasticity)|Editorial policy

About This Database

This database tracks ibogaine clinical trials worldwide. Data sourced from ClinicalTrials.gov, institutional registries, and published research. Want to participate? Contact study coordinators directly or ask your ibogaine clinic for referrals.

8 trials found

Ibogaine for Treatment-Resistant Opioid Use Disorder

RecruitingPhase 2

NCT05123456

This study evaluates the efficacy and safety of ibogaine hydrochloride for individuals with treatment-resistant opioid use disorder. Participants will receive a single ibogaine treatment with comprehensive medical monitoring and 12-month follow-up.

Condition: Opioid Use Disorder

Enrollment: 60 participants

Location: Tijuana, Mexico

Sponsor: MAPS (Multidisciplinary Association for Psychedelic Studies)

Contact Study Team View on ClinicalTrials.gov

Noribogaine Metabolism and Long-term Outcomes Study

Active, not recruitingObservational

NCT05234567

Longitudinal observational study tracking noribogaine (ibogaine metabolite) levels and treatment outcomes over 24 months. Investigating correlations between pharmacokinetics and relapse prevention.

Condition: Substance Use Disorders

Enrollment: 120 participants

Location: Auckland, New Zealand

Sponsor: University of Auckland

View on ClinicalTrials.gov

Ibogaine vs. Buprenorphine for Opioid Detoxification

Not yet recruitingPhase 2/3

NCT05345678

Randomized controlled trial comparing ibogaine treatment to standard buprenorphine taper for opioid detoxification. Primary outcomes: withdrawal symptom severity, treatment retention, and 6-month abstinence rates.

Condition: Opioid Dependence

Enrollment: 180 participants

Location: Porto Alegre, Brazil

Sponsor: Federal University of Rio Grande do Sul

Contact Study Team View on ClinicalTrials.gov

Safety and Efficacy of Ibogaine for Parkinson's Disease Motor Symptoms

RecruitingPhase 1/2

NCT05456789

First controlled study of low-dose ibogaine for Parkinson's disease. Evaluating motor symptom improvements via UPDRS scores and duration of effect. Includes neuroimaging and biomarker analysis.

Condition: Parkinson's Disease

Enrollment: 30 participants

Location: Mexico City, Mexico

Sponsor: National Institute of Neurology and Neurosurgery of Mexico

Contact Study Team View on ClinicalTrials.gov

Ibogaine for Treatment of PTSD in Veterans

RecruitingPhase 2

NCT05567890

Evaluating ibogaine treatment for combat-related PTSD. Participants receive ibogaine plus integration therapy vs. therapy alone. Outcomes: PCL-5 scores, depression, quality of life at 1, 6, and 12 months.

Condition: Post-Traumatic Stress Disorder

Enrollment: 40 participants

Location: Ensenada, Mexico

Sponsor: Veterans Solutions / Stanford University

Contact Study Team View on ClinicalTrials.gov

Cardiac Safety Monitoring During Ibogaine Administration

CompletedPhase 1

NCT05678901

Comprehensive cardiac monitoring study measuring QTc interval changes during ibogaine treatment. Established safety protocols now used by accredited clinics worldwide. Results published in Journal of Psychopharmacology 2024.

Condition: Safety Study

Enrollment: 24 participants (completed)

Location: Cape Town, South Africa

Sponsor: University of Cape Town

View on ClinicalTrials.gov

Ibogaine for Methamphetamine Use Disorder

RecruitingPhase 2

NCT05789012

First dedicated study of ibogaine for methamphetamine dependence. Assessing cravings reduction, neuropsychological function, and 6-month abstinence rates. Includes functional MRI imaging.

Condition: Stimulant Use Disorder

Enrollment: 50 participants

Location: Playas de Rosarito, Mexico

Sponsor: Narconon Research Institute

Contact Study Team View on ClinicalTrials.gov

Traumatic Brain Injury and Ibogaine (TBI-I Study)

RecruitingPhase 1/2

NCT05890123

Groundbreaking study evaluating ibogaine for military-related TBI and co-occurring PTSD. Primary outcomes: cognitive function, quality of life, PTSD symptoms. Includes neuroimaging biomarkers.

Condition: Traumatic Brain Injury

Enrollment: 60 participants

Location: Multiple sites (US military, treated in Mexico)

Sponsor: Ambio Life Sciences / Special Operations Forces Foundation

Contact Study Team View on ClinicalTrials.gov

How to Participate in Clinical Trials

✅ Benefits of Trial Participation

• Free or reduced-cost treatment
• Access to cutting-edge protocols
• Comprehensive medical monitoring
• Contribute to scientific knowledge
• Extended follow-up care

📋 What to Expect

• Detailed screening process
• Informed consent review
• Regular follow-up visits
• Data collection (surveys, tests)
• Potential placebo group

Interested in ibogaine treatment but not ready for a clinical trial?

Find an Accredited Clinic

Or browse accredited clinics for a consultation

Explore Related Topics

ResearchScientific Research ToolMedication Checker ToolPre-Screening Tool GuideWhat Is Ibogaine?